TRVI

Trevi Therapeutics Inc

14.81

Nov 11 • 3:59 PM ET -0.10 (-0.64%)

14.81

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Nov 09, 7:08 PMTrevi starts second Phase 3 OCEAN trial in IPF-related chronic cough, extends cash runway to fund operations and trials into 2030

Peers: SVRA GSK PLRX INSM MLYS MRK SEPN TVRD UPB UTHR

| Held by: VTI IWM VXF IWO IBB SCHA XPH VTWO IHE VHT

Scroll to Statements

Index	RUT
Market Cap	2.11B
Enterprise Value	1.81B
Income	-60.76M
Sales	0.00M
Book/sh	2.12
Cash/sh	2.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	34
IPO	May 07, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.97
P/C	7.05
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	38.86
Current Ratio	38.86
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.40
EPS next Y	-0.66
EPS next Q	-0.15
EPS this Y	-52.08%
EPS next Y	-34.93%
EPS next 5Y	-
EPS past 3/5Y	11.11% 29.44%
Sales past 3/5Y	- -
EPS Y/Y TTM	-6.57%
Sales Y/Y TTM	-
EPS Q/Q	-65.19%
Sales Q/Q	-
Earnings	Nov 09 AMC
EPS/Sales Surpr.	1.29% -

Insider Own	27.67%
Insider Trans	-0.10%
Inst Own	82.12%
Inst Trans	10.77%
ROA	-23.82%
ROE	-24.67%
ROIC	-20.06%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	10.79%
SMA50	4.56%
SMA200	2.23%
Trades

Shs Outstand	142.53M
Shs Float	103.05M
Short Float	16.36%
Short Ratio	8.67
Short Interest	16.86M
52W High	20.22 -26.73%
52W Low	9.82 50.87%
Volatility	9.52% 5.89%
ATR (14)	0.84
RSI (14)	58.65
Beta	1.12
Rel Volume	0.78
Avg Volume	1.94M
Volume	1,518,651

Perf Week	5.93%
Perf Month	20.55%
Perf Quarter	-18.37%
Perf Half Y	-2.98%
Perf YTD	18.33%
Perf Year	22.44%
Perf 3Y	1030.92%
Perf 5Y	1155.51%
Perf 10Y	-
Recom	1.00
Target Price	29.50
Prev Close	14.91
Price	14.81
Change %	-0.64%

Consensus

Strong Buy

Avg. Price Target

$29.50

Implied Upside

+99.1%

Analysts11incl. previous ratings

Rating Distribution11 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 21, 2026	Initiated	BBMO Capital Markets	Outperform	$36	+143.0%
Nov 13, 2025	Initiated	LLeerink Partners	Outperform	$13	-12.3%
Aug 21, 2025	Initiated	MMorgan Stanley	Overweight	$18	+21.5%
Jul 01, 2025	Initiated	CCantor Fitzgerald	Overweight	$25	+68.7%
May 28, 2025	Initiated	HH.C. Wainwright	Buy	$21	+41.7%
Mar 10, 2025	Upgrade	RRaymond James	Outperform → Strong Buy	$9 → $29	+95.7%
Mar 10, 2025	Reiterated	NNeedham	Buy	$8 → $25	+68.7%
Dec 12, 2024	Reiterated	HH.C. Wainwright	Buy	$6 → $7.50	-49.4%
Sep 09, 2024	Resumed	LLeerink Partners	Outperform	$6 → $7	-52.8%
Aug 30, 2024	Initiated	RRaymond James	Outperform	$9	-39.3%
Aug 30, 2024	Initiated	HH.C. Wainwright	Buy	$6	-59.5%
Jun 13, 2024	Initiated	RRodman & Renshaw	Buy	$7	-52.8%
Apr 12, 2023	Initiated	RB. Riley Securities	Buy	$6	-59.5%
Nov 22, 2022	Initiated	SSVB Leerink	Outperform	$6	-59.5%
Jun 03, 2019	Initiated	SSVB Leerink	Outperform	$14	-5.5%
Jun 03, 2019	Initiated	SStifel	Buy	$20	+35.0%
Jun 03, 2019	Initiated	NNeedham	Buy	$18	+21.5%
Jun 03, 2019	Initiated	BBMO Capital Markets	Outperform	$15	+1.2%

Nov-09-26 06:52PM	Trevi Therapeutics Matches Loss Estimates As FDA Alignment And A Cleared Field Offset Slipping Timelines And A Narrower Runway (Earnings Whispers) +6.84%
04:05PM	Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-03-26 01:23PM	Trevi's Third-Quarter Report Hinges On OCEAN-2 Start And Countdown To LAKE Interim Look (Earnings Whispers)
Nov-02-26 04:05PM	Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026 (GlobeNewswire)
Oct-27-26 07:30AM	Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference (GlobeNewswire) +6.71%
07:30AM	Loading…
Oct-13-26 07:30AM	Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting (GlobeNewswire)
Oct-08-26 10:09AM	Top 4 Healthcare Stocks Backed by Raymond James Analysts (Investing.com)
Sep-03-26 07:30AM	Trevi Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-26-26 07:30AM	Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 (GlobeNewswire)
Aug-07-26 01:08AM	Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ... (GuruFocus.com)
Aug-06-26 04:05PM	Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-30-26 04:05PM	Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 (GlobeNewswire)
Jul-28-26 07:30AM	Trevi Therapeutics to Participate in Upcoming August Conferences (GlobeNewswire)
Jun-17-26 07:30AM	Trevi Therapeutics Announces Upcoming June and July Event Schedule (GlobeNewswire) +6.30%
May-05-26 04:05PM	Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
04:05PM	Loading…
Apr-30-26 04:05PM	Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference (GlobeNewswire)
Apr-28-26 04:05PM	Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 (GlobeNewswire)
Apr-23-26 04:05PM	Trevi Therapeutics to Participate in Upcoming May Events (GlobeNewswire)
Apr-20-26 04:05PM	Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -5.06%
Apr-16-26 10:42PM	Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire)
04:08PM	Trevi Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Apr-01-26 07:30AM	Trevi Therapeutics to Participate in Upcoming Events (GlobeNewswire)
Mar-17-26 11:01PM	Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
04:05PM	Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates (GlobeNewswire)
05:11AM	lululemon earnings on tap after stock swoon (MarketWatch)
04:17AM	Stock Market Today: Dow, S&P 500 and Nasdaq futures shake off early losses; Brent moves back above $100 a barrel on continued Iran war. (MarketWatch)
Mar-11-26 05:27AM	Zacks.com featured highlights include Trevi, Metalla Royalty & Streaming and Vermilion (Zacks)
Mar-10-26 04:05PM	Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 (GlobeNewswire)
Mar-09-26 03:05PM	Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March (Zacks) -12.03%
07:30AM	Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough (GlobeNewswire)
07:30AM	Loading…
Mar-02-26 07:30AM	Trevi Therapeutics to Participate in Upcoming March Conferences (GlobeNewswire) +5.45%
Feb-23-26 09:55AM	Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect? (Zacks)
Feb-17-26 07:30AM	Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-22-26 12:30PM	Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) (PR Newswire) +6.21%
Jan-08-26 07:30AM	Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat)
Dec-21-25 07:31AM	Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change (Insider Monkey)
Dec-04-25 07:30AM	Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer (PR Newswire)
Nov-14-25 12:03AM	Trevi Therapeutics Inc (TRVI) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-13-25 04:05PM	Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (PR Newswire)
Nov-06-25 04:05PM	Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 (PR Newswire)
Nov-04-25 07:30AM	Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference (PR Newswire)
Oct-08-25 07:30AM	Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting (PR Newswire)
Sep-18-25 07:30AM	Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025 (PR Newswire) +7.02%
Sep-11-25 03:31AM	Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley (Insider Monkey)
Aug-28-25 07:30AM	Trevi Therapeutics to Participate in Upcoming September Conferences (PR Newswire) -9.87%
Aug-21-25 09:36AM	CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 04:05PM	Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (PR Newswire)
Jul-31-25 04:05PM	Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 (PR Newswire)
Jul-29-25 07:30AM	Trevi Therapeutics to Participate in Upcoming August Conferences (PR Newswire)
Jul-11-25 09:55AM	Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know (Zacks)
Jul-01-25 07:30AM	Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism (PR Newswire)
Jun-05-25 04:30PM	Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares (PR Newswire)
Jun-03-25 10:15PM	Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock (PR Newswire) -5.78% +10.59%
Jun-02-25 04:01PM	Trevi Therapeutics Announces Proposed Public Offering of Common Stock (PR Newswire)
07:00AM	Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough (PR Newswire)
Jun-01-25 04:00PM	Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough (PR Newswire)
May-29-25 02:52PM	H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating (Insider Monkey)
07:30AM	Trevi Therapeutics to Participate in Upcoming June Conferences (PR Newswire)
May-20-25 07:00AM	Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough (PR Newswire)
May-14-25 09:55AM	Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High? (Zacks)
May-09-25 03:43AM	Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com)
May-08-25 04:05PM	Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (PR Newswire)
May-01-25 04:05PM	Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 (PR Newswire)
Apr-03-25 07:30AM	Trevi Therapeutics to Participate in Upcoming April Investor Conferences (PR Newswire)
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-19-25 07:36AM	Q4 2024 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ... (GuruFocus.com)
Mar-18-25 04:05PM	Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates (PR Newswire)
Mar-11-25 04:05PM	Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 (PR Newswire)
Mar-10-25 11:30AM	Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps (Benzinga) +41.16%
06:00AM	Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough (PR Newswire)
Mar-09-25 04:00PM	Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough (PR Newswire)
Feb-27-25 07:30AM	Trevi Therapeutics to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-26-25 10:47AM	Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPF (Clinical Trials Arena)
Feb-25-25 07:30AM	Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough (PR Newswire)
Feb-20-25 02:30PM	Why Trevi Therapeutics (TRVI) Is Advancing Today (Insider Monkey) +5.03%
Jan-30-25 07:30AM	Trevi Therapeutics to Participate in Upcoming February Investor Conferences (PR Newswire)
Jan-08-25 12:00PM	What Makes Trevi Therapeutics (TRVI) a New Buy Stock (Zacks)
07:30AM	Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference (PR Newswire)
Dec-16-24 07:36AM	Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering (PR Newswire)
Dec-13-24 07:10AM	Trevis chronic cough trial in IPF subjects continues without sample size change (Clinical Trials Arena) +15.83%
Dec-12-24 09:47AM	Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? (Benzinga) +44.58%
07:30AM	Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough (PR Newswire)
Dec-03-24 04:05PM	Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine (PR Newswire) -6.47%
Nov-21-24 07:30AM	Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-07-24 01:18PM	Q3 2024 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.45%
02:21AM	Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... (GuruFocus.com)
Nov-06-24 04:05PM	Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (PR Newswire)
Oct-30-24 04:05PM	Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 (PR Newswire)
Oct-23-24 05:02PM	Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc. (GuruFocus.com)
Oct-21-24 07:30AM	Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough (PR Newswire) +7.37%
Oct-15-24 07:30AM	Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences (PR Newswire)
Oct-09-24 05:58PM	Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -5.08%
Oct-03-24 04:05PM	Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program (PR Newswire) -5.33%
Sep-30-24 05:30PM	Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer (PR Newswire) -6.89%
Sep-26-24 07:30AM	Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 (PR Newswire)
Sep-04-24 04:05PM	Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 (PR Newswire) +5.08%
Aug-30-24 09:33AM	Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls (The Fly) +8.59%
Aug-28-24 07:30AM	Trevi Therapeutics to Participate in September Investor and Medical Conferences (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heffernan Michael Thomas	Director	Sep 15 '26	Option Exercise	3.19	39,473	126,103	27,403	Sep 17 04:55 PM
Heffernan Michael Thomas	Director	Sep 15 '26	Sale	15.09	39,473	595,806	6,351	Sep 17 04:55 PM
MICHAEL HEFFERNAN	Director	Sep 15 '26	Proposed Sale	15.89	39,473	627,226		Sep 15 04:42 PM
Galletta Christopher	See Remarks	Dec 02 '25	Option Exercise	0.51	4,225	2,159	26,095	Dec 03 04:16 PM

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Co-FounderMs. Jennifer L. Good

Chief Development OfficerDr. James V. Cassella Ph.D.

Chief Commercial OfficerDr. Farrell Simon Pharm.D.

Co-Founder & Chief Scientific OfficerDr. Thomas R. Sciascia M.D.

Chief Financial Officer & Principal Financial OfficerMr. David C. Hastings CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

TRVI

Trevi Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.